68Ga-NI-FAPI

N/A

Report date: 2026/03/20 20:03:07
NME

Base Information

Drug Name68Ga-NI-FAPI
Drug Alias Name68Ga-NI-FAPI
ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionPositron-emission tomography enhancersFibroblast activation protein alpha modulators
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsHypoxiaImmune System DiseasesCardiomyopathy, Hypertrophic +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesFirst Affiliated Hospital Of Fujian Medical University
China Registration ClassN/A

Develop Information

Active CompaniesPeking Union Medical College Hospital
Inactive CompaniesFirst Affiliated Hospital Of Fujian Medical University
Active IndicationsHypoxiaCardiomyopathy, HypertrophicPulmonary Fibrosis +[4] 
Inactive IndicationsImmune System DiseasesCardiovascular DiseasesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A